As senescence induction is an emerging strategy for the treatment of HCC, it is possible that intervening in the MKL1/2—SRF-MYOF signaling pathway may contribute to the treatment of hepatocellular cancer [74]. The gene discussed is MYOF; the disease is hepatocellular carcinoma.